BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 35254121)

  • 1. Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test.
    Chan MMH; Leung KY; Zhang RRQ; Liu D; Fan Y; Khong MKW; Tam AR; Chen H; Yuen KY; Hung IFN; Chan KH
    Microbiol Spectr; 2022 Apr; 10(2):e0099321. PubMed ID: 35254121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.
    Patel EU; Bloch EM; Clarke W; Hsieh YH; Boon D; Eby Y; Fernandez RE; Baker OR; Keruly M; Kirby CS; Klock E; Littlefield K; Miller J; Schmidt HA; Sullivan P; Piwowar-Manning E; Shrestha R; Redd AD; Rothman RE; Sullivan D; Shoham S; Casadevall A; Quinn TC; Pekosz A; Tobian AAR; Laeyendecker O
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
    Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL
    Front Immunol; 2021; 12():748291. PubMed ID: 34867975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference.
    Graninger M; Jani CM; Reuberger E; Prüger K; Gaspar P; Springer DN; Borsodi C; Weidner L; Rabady S; Puchhammer-Stöckl E; Jungbauer C; Höltl E; Aberle JH; Stiasny K; Weseslindtner L
    Microbiol Spectr; 2023 Feb; 11(1):e0231422. PubMed ID: 36622205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of IgM, IgG, IgA and neutralizing antibody responses to SARS-CoV-2 infection and mRNA vaccination.
    Fleischmann CJ; Bulman CA; Yun C; Lynch KL; Wu AHB; Whitman JD
    J Med Microbiol; 2023 Jan; 72(1):. PubMed ID: 36748419
    [No Abstract]   [Full Text] [Related]  

  • 10. Dynamic observation of SARS-CoV-2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVID-19 vaccination.
    Jiang R; Dou X; Li M; Wang E; Hu J; Xiong D; Zhang X
    J Clin Lab Anal; 2022 Apr; 36(4):e24325. PubMed ID: 35235705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays.
    Nandakumar V; Profaizer T; Lozier BK; Elgort MG; Larragoite ET; Williams ESCP; Solis-Leal A; Lopez JB; Berges BK; Planelles V; Rychert J; Slev PR; Delgado JC
    Arch Pathol Lab Med; 2021 Oct; 145(10):1212-1220. PubMed ID: 34181714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay.
    Kang K; Huang L; Ouyang C; Du J; Yang B; Chi Y; He S; Ying L; Chen G; Wang J
    J Med Virol; 2021 May; 93(5):2838-2847. PubMed ID: 33231312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
    Pieri M; Nicolai E; Nuccetelli M; Sarubbi S; Tomassetti F; Pelagalli M; Minieri M; Terrinoni A; Bernardini S
    Arch Virol; 2022 May; 167(5):1285-1291. PubMed ID: 35377034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
    Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
    JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of qualitative and semi-quantitative cut offs for rapid diagnostic lateral flow test in relation to serology for the detection of SARS-CoV-2 antibodies: findings of a prospective study.
    Peghin M; Bontempo G; De Martino M; Palese A; Gerussi V; Graziano E; Fabris M; D'Aurizio F; Sbrana F; Ripoli A; Curcio F; Isola M; Tascini C
    BMC Infect Dis; 2022 Oct; 22(1):810. PubMed ID: 36316641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
    Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
    Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sars-Cov-2 Infection Screening Using Two Serological Testing Methods.
    Arinola OG; Edem VF; Rahamon SK; Yaqub SA; Fashina AO; Alonge TO
    Niger J Physiol Sci; 2020 Dec; 35(2):117-121. PubMed ID: 34009193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.